These findings led to the approval by the USA Food and Drug Administration (FDA) and European Medicines Agency (EMA) of the three CDK4/6i—palbociclib, ribociclib and abemaciclib—in combination with ET, as first-line and second-line treatments of metastatic HR+/HER2− BC. The gene discussed is CDK4; the disease is breast cancer.